Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The average age of cancer patients is getting younger, as experts are ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...